Why CareDx Stock Soared Today

CDNA surged more than 22% after the company posted third-quarter 2026 revenue of $139 million, up 39% year over year, and raised its full-year outlook.

Testing services drove the beat. Testing services revenue jumped 65%, while testing volumes rose 51%. Those two figures point to demand growth, not just pricing, as the engine behind the top-line gain (interpretation: volume growth of that size suggests broader adoption of its diagnostics).

Management lifted full-year revenue guidance to $525 million, implying 38% growth. It also raised its adjusted EBITDA target to a range of $90 million to $100 million. The guidance raise matters as much as the quarter itself: it signals management expects the third-quarter pace to hold through year-end, since 39% quarterly growth sits close to the 38% full-year figure (interpretation).

The market's 22% reaction reflects a stock repricing on both growth and profitability targets. The EBITDA range gives investors a concrete earnings anchor, not just a revenue story.